NewAmsterdam Pharma (NAMS) Income Statement (2023 - 2026)
Income Statement report data from Mar 31, 2023 to Mar 31, 2026 for NewAmsterdam Pharma (NAMS).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and COGS | |||||||||||||
Total Revenue | 3.04M (+10033.33%) | 30K (-91.43%) | 350K (-98.17%) | 19M (+542.62%) | 2.98M (-76.66%) | 13M (-56.13%) | 29M (+1176.75%) | 2.28M (+62.86%) | 1.40M (+75.00%) | 800K (-72.79%) | 2.94M (+70.93%) | 1.72M (-80.07%) | 8.63M |
Operating Expenses | |||||||||||||
Research And Development | 38M (-1.50%) | 39M (+24.60%) | 31M (+12.54%) | 28M (-38.50%) | 45M (+28.22%) | 35M (-2.24%) | 36M (-6.98%) | 38M (-9.55%) | 42M (+2.76%) | 41M (-4.80%) | 43M (+26.30%) | 34M (-15.04%) | 40M |
Selling General And Administrative | 23M (-14.48%) | 27M (+11.83%) | 25M (-10.05%) | 27M (+0.41%) | 27M (+28.61%) | 21M (+14.67%) | 18M (+11.71%) | 16M (+14.05%) | 14M (+36.45%) | 11M (+15.99%) | 9.13M (-7.40%) | 9.86M (+22.33%) | 8.06M |
Operating Expenses | 61M (-6.89%) | 66M (+18.96%) | 55M (+1.30%) | 55M (-23.81%) | 72M (+28.39%) | 56M (+3.49%) | 54M (-1.35%) | 55M (-3.57%) | 57M (+9.64%) | 52M (-1.18%) | 53M (+18.78%) | 44M (-8.83%) | 48M |
Depreciation And Amortization | 60K | -60.00K | 130K (+18.18%) | 110K (+120.00%) | 50K | -60.00K | 90K (+28.57%) | 70K (+250.00%) | 20K (-50.00%) | 40K | - | - | 10K |
Operating Income | |||||||||||||
Operating Income | -58.42M (-11.46%) | -65.98M (+19.66%) | -55.14M (+54.76%) | -35.63M (-48.30%) | -68.92M (+59.43%) | -43.23M (+72.92%) | -25.00M (-52.44%) | -52.57M (-5.25%) | -55.48M (+8.64%) | -51.07M (+3.05%) | -49.56M (+16.67%) | -42.48M (+6.60%) | -39.85M |
Ebit | -58.42M (-11.46%) | -65.98M (+19.66%) | -55.14M (+54.76%) | -35.63M (-48.30%) | -68.92M (+59.43%) | -43.23M (+72.92%) | -25.00M (-52.44%) | -52.57M (-5.25%) | -55.48M (+8.64%) | -51.07M (+3.05%) | -49.56M (+16.67%) | -42.48M (+6.60%) | -39.85M |
EBITDA | -58.36M (-11.63%) | -66.04M (+20.03%) | -55.02M (+54.86%) | -35.53M (-48.41%) | -68.87M (+59.09%) | -43.29M (+73.79%) | -24.91M (-52.56%) | -52.51M (-5.34%) | -55.47M (-3.78%) | -57.65M (+22.32%) | -47.13M (+23.09%) | -38.29M (-3.89%) | -39.84M |
Other Income / Expenses | |||||||||||||
Interest Income | 5.65M (-12.67%) | 6.47M (-3.58%) | 6.71M (-4.96%) | 7.06M (-3.95%) | 7.35M (+63.70%) | 4.49M (+1.13%) | 4.44M (-8.83%) | 4.87M (+58.12%) | 3.08M (+15.36%) | 2.67M (-12.75%) | 3.06M (-33.62%) | 4.61M (+390.43%) | 940K |
Net Interest Income | 5.65M (-12.67%) | 6.47M (-3.58%) | 6.71M (-4.96%) | 7.06M (-3.95%) | 7.35M (+63.70%) | 4.49M (+1.13%) | 4.44M (-8.83%) | 4.87M (+58.12%) | 3.08M (+15.36%) | 2.67M (-12.75%) | 3.06M (-33.62%) | 4.61M (+390.43%) | 940K |
Net Income | |||||||||||||
Income Before Tax | -48.44M (-35.34%) | -74.92M (+4.06%) | -72.00M (+314.75%) | -17.36M (-56.08%) | -39.53M (-57.12%) | -92.18M (+453.63%) | -16.65M (-57.32%) | -39.01M (-58.40%) | -93.77M (+89.55%) | -49.47M (+4.96%) | -47.13M (+23.09%) | -38.29M (-8.88%) | -42.02M |
Income Tax Expense | - | - | - | - | - | - | - | - | - | 30K | - | - | - |
Net Income From Continuing Operations | -48.44M (-35.34%) | -74.92M (+4.06%) | -72.00M (+314.75%) | -17.36M (-56.08%) | -39.53M (-57.12%) | -92.18M (+453.63%) | -16.65M (-57.32%) | -39.01M (-58.40%) | -93.77M (+89.47%) | -49.49M (+5.01%) | -47.13M (+23.09%) | -38.29M (-8.88%) | -42.02M |
Net Income | -48.44M (-35.34%) | -74.92M (+4.06%) | -72.00M (+314.75%) | -17.36M (-56.08%) | -39.53M (-57.12%) | -92.18M (+453.63%) | -16.65M (-57.32%) | -39.01M (-58.40%) | -93.77M (+89.47%) | -49.49M (+5.01%) | -47.13M (+23.09%) | -38.29M (-8.88%) | -42.02M |
Comprehensive Income Net Of Tax | -49.01M (-75.92%) | -203.49M (+183.85%) | -71.69M (+310.36%) | -17.47M (-55.84%) | -39.56M (-83.62%) | -241.55M (+1350.75%) | -16.65M (-57.32%) | -39.01M (-58.40%) | -93.77M (-47.00%) | -176.94M (+275.43%) | -47.13M (+23.09%) | -38.29M (-8.88%) | -42.02M |